In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

This brief explores what access to care, coordination of care, and quality of care look like for older adults with health ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

AstraZeneca to showcase innovation in infectious disease protection at ESCMID Global 2025: Cambridge, UK Thursday, April 10, 2025, 15:00 Hrs [IST] AstraZeneca will share new data ...

S&P Global expects inflation to remain closer to 3.0% in 2025 as tariffs result in higher prices along the domestic supply ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...